Location: | Sutton |
---|---|
Salary: | £31,445 to £33,100 Commencement on the salary range is subject to comparable skills and experience |
Hours: | Full Time |
Contract Type: | Fixed-Term/Contract |
Placed On: | 16th October 2025 |
---|---|
Closes: | 31st October 2025 |
Key Information
Reporting to: Charlotte Pawlyn
Duration of Contract: Fixed Term for 12 months
Hours per week: 35 hours per week (Full Time)
Location: Sutton
Job Details
Under the guidance of Dr Chalotte Pawlyn, we are seeking to recruit a Scientific Officer to contribute to our work understanding mechanisms of resistance to therapies used to treat the bone marrow cancer myeloma. The successful candidate will play a key role in the isolation of myeloma cells from patient samples and downstream processing, experiments and storage. Additionally the SO will support a range of ongoing molecular and cell biology experiments using cell lines and primary samples within the team, including cell viability assays, flow cytometry, qPCR and Western blotting. There will be opportunities to gain experience in novel techniques and explore new avenues of research.
About you
The successful candidate must have:
Department/Directorate Information
Myeloma Biology and Therapeutics Group
Dr Charlotte Pawlyn's team Myeloma Biology and Therapeutics focuses on identifying and validating therapeutic targets for the treatment of immunomodulatory drug resistant and high-risk multiple myeloma. Myeloma is a bone marrow cancer and the second most common haematological malignancy. Immunomodulatory drugs are the “prototype” of targeted protein degradation approaches. Outcomes for patients have improved over the last few decades following the introduction of proteasome inhibitors and immunomodulatory agents. However, patients almost all inevitably relapse and understanding the mechanisms of resistance to these commonly used agents is key to improving outcomes.
The team sits within the Division of Cancer Therapeutics which has an unrivalled track record at discovering novel cancer treatments and biomarkers. Their work has made The Institute of Cancer Research the world’s most successful academic centre at discovering new cancer drugs. We also work closely with the Centre of Protein Degradation
What we offer
We encourage all applicants to access the job pack attached for more detailed information regarding this role. For an informal discussion regarding the role, please contact Charlotte Pawlyn via Email on Charlotte.Pawlyn@icr.ac.uk
Type / Role:
Subject Area(s):
Location(s):